Over 80% of drug manufacturers are unprepared to meet the legal challenges of more than $60 billion in pharmaceutical patent losses.
Is your company one of them?
Don’t be caught off guard. Attend the only event dedicated to providing brand name and generic legal professionals with the tools needed to master the strategies, standards and tactics of Paragraph IV litigation.
As brand name and generic pharmaceutical companies make their dissent down the patent cliff they have become all too familiar with the pecuniary perils of patent loss and the economic consequences associated with the decline of Hatch-Waxman market exclusivity. The industry has entered an era of “extreme” Paragraph IV litigation where the monetary ante has never been higher and as a result is now seeking redress in forums beyond the federal courts.
To help you respond to the challenges of this new era, ACI’s 7th Annual Paragraph IV Disputes conference will guarantee your access to the leading legal minds in this area. A “who’s who” of Hatch-Waxman litigators — for both brand names and generics — will help you conquer the patent crisis of 2013 by addressing such industry shaping topics as:
• The impact of the AIA on Hatch –Waxman litigation
• The implications of FDASIA for Paragraph IV litigation
• The scope of the safe harbor and acts of infringement
• Prior art obviousness and obvious-type double patenting
• Inducement of infringement and divided infringement
• Inequitable conduct
Hear also from renowned federal jurists and a key official from the Federal Trade Commission. Learn firsthand how the bench analyzes the theories of your case and what the FTC deems as “fair and foul” in the settlement of pharmaceutical patent disputes.
For more information, click here.